TG Therapeutics
(NASDAQ) TGTX
TG Therapeutics Financials at a Glance
Market Cap
$5.03B
Revenue (TTM)
$616.29M
Net Income (TTM)
$447.18M
EPS (TTM)
$2.78
P/E Ratio
11.35
Dividend
$0.00
Beta (Volatility)
1.83 (High)
Dividend
$0.00
Beta (Volatility)
1.83 (High)
Price
$31.55
Volume
76,211
Open
$31.85
Price
$31.55
Volume
76,211
Open
$31.85
Previous Close
$31.55
Daily Range
$31.34 - $32.13
52-Week Range
$25.28 - $46.48
Dividend
$0.00
Beta (Volatility)
1.83 (High)
Price
$31.55
Volume
76,211
Open
$31.85
Previous Close
$31.55
Daily Range
$31.34 - $32.13
52-Week Range
$25.28 - $46.48
TGTX News
TGTX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout TG Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
399
CEO
Michael Sean Weiss
Website
www.tgtherapeutics.comHeadquarters
Morrisville, NY 10014, US
TGTX Financials
Key Financial Metrics (TTM)
Gross Margin
84%
Operating Margin
20%
Net Income Margin
73%
Return on Equity
103%
Return on Capital
14%
Return on Assets
42%
Earnings Yield
8.81%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$5.03B
Shares Outstanding
159.69M
Volume
76.21K
Short Interest
0.00%
Avg. Volume
2.10M
Financials (TTM)
Gross Profit
$515.33M
Operating Income
$123.32M
EBITDA
$134.36M
Operating Cash Flow
$24.77M
Capital Expenditure
$214.00K
Free Cash Flow
$24.99M
Cash & ST Invst.
$141.97M
Total Debt
$260.73M
TG Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$192.57M
+78.0%
Gross Profit
$154.37M
+66.4%
Gross Margin
80.16%
N/A
Market Cap
$5.03B
N/A
Market Cap/Employee
$14.29M
N/A
Employees
352
N/A
Net Income
$23.04M
-1.3%
EBITDA
$51.69M
+58.7%
Quarterly Fundamentals
Net Cash
$118.76M
-307.3%
Accounts Receivable
$305.63M
+136.6%
Inventory
$125.59M
+13.7%
Long Term Debt
$259.69M
+2.8%
Short Term Debt
$1.04M
-9.8%
Return on Assets
42.06%
N/A
Return on Invested Capital
13.56%
N/A
Free Cash Flow
$19.59M
+176.4%
Operating Cash Flow
$19.66M
+176.7%